NCT05035381 2021-09-05
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
Tianjin Medical University Cancer Institute and Hospital
Shanghai JMT-Bio Inc.
SuZhou Stainwei Biotech Inc.
Biotech Pharmaceutical Co., Ltd.
National Cancer Institute (NCI)